IFNG and rheumatoid arthritis: Considering that zoledronate and IFNγ have already been approved for the clinical treatment of osteoporosis and internal rheumatoid arthritis, respectively, the combined delivery of these two components in a nanostructure will provide an effective strategy with great translational promise to overcome the poor prognosis after clinically incomplete RFA.